Compare BLD & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLD | EXAS |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 11.0B |
| IPO Year | N/A | N/A |
| Metric | BLD | EXAS |
|---|---|---|
| Price | $437.19 | $101.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 20 |
| Target Price | ★ $429.38 | $77.94 |
| AVG Volume (30 Days) | 260.8K | ★ 10.8M |
| Earning Date | 11-04-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 19.67 | N/A |
| Revenue | ★ $5,236,045,000.00 | $3,082,033,000.00 |
| Revenue This Year | $2.39 | $19.40 |
| Revenue Next Year | $13.47 | $13.51 |
| P/E Ratio | $22.16 | ★ N/A |
| Revenue Growth | N/A | ★ 14.47 |
| 52 Week Low | $266.26 | $38.81 |
| 52 Week High | $461.49 | $101.95 |
| Indicator | BLD | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 50.91 | 89.65 |
| Support Level | $418.75 | $100.95 |
| Resistance Level | $454.91 | $101.95 |
| Average True Range (ATR) | 13.90 | 0.35 |
| MACD | -0.60 | -0.87 |
| Stochastic Oscillator | 40.77 | 61.17 |
TopBuild Corp is an installer and distributor of insulation products. Its operating segments involve the Installation and Specialty Distribution segment. The installation segment provides insulation installation services nationwide through contractor services business. Speciality Distribution segment distributes building and mechanical insulation, insulation accessories and other building product materials for the residential, commercial, and industrial end markets. The majority of revenue is earned from the installation segment. Its main customers are contractors. Other products include gutters, after-paint, garage doors, fireplaces, and fireproofing and stopping. TopBuild operates majorly in the United States.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.